Delivery Order SPE2DB22D1041-SPE2DB25FUBQ6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count packages) under a firm fixed-price contract valued at $3,337.56. The order was competitively awarded without set-aside provisions and is scheduled for completion by July 25, 2025. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, reflecting the pharmaceutical distributor's role in supplying critical medications to federal...
- The Defense Logistics Agency awarded a delivery order valued at approximately $25.5K to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by July 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Multaq is a cardiac antiarrhythmic medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $11,496.80 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Multaq 400 mg tablets (60-count packages). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract calls for delivery by August 6, 2025, and performance will occur at the contractor's Conshohocken facility. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,061.44 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. Multaq is a cardiovascular medication used in the treatment of atrial fibrillation, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at approximately $7K to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price contract with no set-aside designation was executed on July 28, 2025, with an ultimate completion date of July 29, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,170.01 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $17,446.83 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed-price contract with an ultimate completion date of August 19, 2025. This non-set-aside delivery order represents a single procurement action drawn from AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $1,550.46 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Multaq (dronedarone) is an antiarrhythmic medication used in the...
- The Defense Logistics Agency awarded a $51,938.18 delivery order to AmerisourceBergen Drug Corp for 60-tablet units of Multaq 400 mg tablets, a pharmaceutical product used in cardiac arrhythmia management. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 13, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply Multaq 400 mg tablets. The $26,758.04 delivery order was placed under an existing $999,999,999.00 indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp to provide a comprehensive range of pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBQ6Delivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $19,665.68 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). The contract, which is a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA, was competitively awarded without set-aside designation and is scheduled for completion by September 3, 2025. Multaq is an antiarrhythmic medication used in military and veteran healthcare systems, reflecting the DLA's ongoing procurement of specialized pharmaceuticals to support the Defense Health Agency and other federal medical supply chains. This delivery order falls under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania—the location of performance for this order—AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. The company's extensive federal contract portfolio demonstrates its capability to meet competitive procurement requirements and support global military healthcare programs through flexible contract vehicles designed to streamline pharmaceutical distribution to federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.7k | 9/2/25 |